Theralink Technologies Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Hi, I'm Mick Ruxin. I'm the CEO of Theralink Technologies. Here are the usual disclaimers.
So let's begin by telling you that Theralink is at an inflection point in its history. We have recently received our Medicare go-ahead to begin billing Medicare, which means that we'll be able to take the next step and bill other third-party payers. So we've now gone from an R&D company as of January 1 to an operational revenue-generating entity.
So Theralink is solving a significant problem in oncology treatment by providing game-changing technology that can predict which FDA-approved drug is effective in each cancer. So the company is a precision medicine company. We are a proteomic company, which is the next step beyond genomics, and we'll talk a little bit about this in the presentation.
Our key recent milestones is that early results show greater than 90% actionability. So what does this mean?That means in our latest clinical trial, when the oncologist receive their results, they actually found that 90% of the time, they
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
